



THE UNITED STATES PATENT AND TRADEMARK OFFICE

Re application of

: **Confirmation No. 1804**

Hideakira YOKOYAMA et al.

: Attorney Docket No. 2004\_1365A

Serial No. 10/506,512

: Group Art Unit 1618

Filed December 22, 2004

: Examiner Blessing M. Fubara

LIQUID MATRIX TRANSFORMING  
ITS PHASE IN LIVING BODY AND  
ORAL LIQUID PREPARATION

: **Mail Stop Amendment**

**SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

THE COMMISSIONER IS AUTHORIZED  
TO CHARGE ANY DEFICIENCY IN THE  
FEE FOR THIS PAPER TO DEPOSIT  
ACCOUNT NO. 23-0975.

Sir:

Pursuant to the provisions of 37 CFR 1.56, 1.97 and 1.98, Applicants request consideration of the references listed on attached form PTO-1449 and any additional information identified below in paragraph 3. A legible copy of each reference listed on the Form PTO-1449 is enclosed.

1a. [X] This Information Disclosure Statement is submitted:

within three months of the filing date (or of entry into the National Stage) of the above-entitled application, **or**

before the mailing of a first Office Action on the merits or the mailing of a first Office Action after the filing of an RCE,

**and thus no certification and/or fee is required.**

1b. ☐ This Information Disclosure Statement is submitted

after the events of above paragraph 1a and prior to the mailing date of a final Office Action or a Notice of Allowance or an action which otherwise closes prosecution in the application, and thus:

(1) ☐ the certification of paragraph 2 below is provided, **or**

(2) ☐ the fee of \$180.00 specified in 37 CFR 1.17(p) is enclosed.

1c. ☐ This Information Disclosure Statement is submitted:

after the mailing date of a final Office Action or Notice of Allowance or action which otherwise closes prosecution in the application, and prior to payment of the issue fee, and thus:

**the certification of paragraph 2 below is provided, and**

**the fee of \$180.00 specified in 37 CFR 1.17(p) is enclosed.**

2. It is hereby certified

a. ☐ that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the Statement, or

b. ☐ that no item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of the person signing the certification after making reasonable inquiry, was known to any individual designated in §1.56(c) more than three months prior to the filing of the Statement.

3. ☐ Consideration of the following list of additional information (including any copending or abandoned U.S. application, prior uses and/or sales, etc.) is requested.


4. For each non-English language reference listed on the attached form PTO-1449, reference is made to:
- a. ☐ a full or partial English language translation submitted herewith,
  - b. ☐ a foreign patent office search report (in the English language) submitted herewith,
  - c. ☐ the concise explanation contained in the specification of the present application at page,
  - d. ☐ the concise explanation set forth in the attached English language abstract,
  - e. ☐ the concise explanation set forth below or on a separate sheet attached to the reference:
5. ☒ A foreign patent office communication citing one or more of the references is enclosed.
6. ☒ Statement Under 37 CFR 1.704(d)

Each item of information contained in the Information Disclosure Statement was first cited in any communication from a foreign Patent Office (copy enclosed) in a counterpart application, and this communication was not received by any individual designated in §1.56(c) more than thirty days prior to the filing of the Information Disclosure Statement.

Respectfully submitted,

Hideakira YOKOYAMA et al.

By:



Michael R. Davis

Registration No. 25,134

Attorney for Applicants


MRD/pth  
Washington, D.C. 20006-1021  
Telephone (202) 721-8200  
Facsimile (202) 721-8250  
January 26, 2007

## INFORMATION DISCLOSURE STATEMENT

FORM PTO 1449 (modified)

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICELIST OF REFERENCES CITED BY APPLICANT(S)  
(Use several sheets if necessary)

Date Submitted to PTO: January 26, 2007

ATTY DOCKET NO.  
2004\_1365ASERIAL NO.  
10/506,512APPLICANT  
Hideakira YOKOYAMA et al.FILING DATE  
December 22, 2004GROUP  
1618

## U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA						
	AB						
	AC						

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
	AD						
	AE						
	AF						
	AG						

## OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Pages, Etc.)

	AH	Shozo Miyazaki et al., "Oral sustained delivery of theophylline using in-situ gelation of sodium alginate", Journal of Controlled Release, 67, pages 275-280, 2000.
	AI	N. Kawasaki et al., "Thermally reversible xyloglucan gels as vehicles for oral drug delivery", International Journal of Pharmaceutics, 181, pages 227-234, 1999.
	AJ	Shozo Miyazaki et al., "In situ-gelling gellan formulations as vehicles for oral drug delivery", Journal of Controlled Release, 60, pages 287-295, 1999.
	AK	Hirokazu Katayama et al., "Sustained Release Liquid Preparation Using Sodium Alginate for Eradication of <i>Helicobacter pylori</i> ", Biol. Pharm. Bull. 22(1), pages 55-60, 1999.
	AL	S. Miyazaki et al., "Comparison of in situ gelling formulations for the oral delivery of cimetidine", International Journal of Pharmaceutics, 220, pages 161-168, 2001.
	AM	Vijay R. Patel et al., "Preparation and Characterization of Freeze-dried Chitosan-Poly(Ethylene Oxide) Hydrogels for Site-Specific Antibiotic Delivery in the Stomach", Pharmaceutical Research, Vol. 13, No. 4, pages 588-593, 1996.
	AN	Victor J. Morris et al., "Cold Setting Alginate-pectin Mixed Gels", J. of the Science of Food and Agriculture, 35, pages 1370-1376, 1984.

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of form with next communication to applicant.